{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-032547","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.329003+00:00","generated_at":"2026-06-16T16:52:13.264377+00:00","sec_items":["1.01","2.03","3.02","3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allarity raises $7.5M in public offering; restructures debt and preferred stock with 3i, LP","bullets":["Gross proceeds $7.5M from offering of 2.87M shares, pre-funded warrants for 7.13M shares, and common warrants for 10M shares at $0.85.","3i, LP provided $350K loan converted to 486 Series A shares; exchanged Series C for 4,027 Series A shares.","Company paid $3.35M to cancel all outstanding debt to 3i and repurchased 1,550 Series A shares for $1.65M.","Series A preferred stock amended: redemption right and dividend eliminated; conversion price set at $0.75.","Exchange warrant issued to 3i for 12.6M common shares at $0.75 exercise price."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-032547","json":"https://secwatch.observer/filing/0001213900-23-032547.json","markdown":"https://secwatch.observer/filing/0001213900-23-032547.md","text":"https://secwatch.observer/filing/0001213900-23-032547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/ea177302-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T16:52:13.264377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a02a21f07c395e8e79b0d853d9988d5e85b67919","claim":"Allarity Therapeutics, Inc.: Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to eliminate redemption right and dividend and adjust conversion price (effective 2023-04-21).","evidence_excerpt":"On April 21, 2023, in connection with the transactions contemplated under the Exchange Agreement, the Company filed an Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “Amended and Restated Series A COD”) with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-04-21"}],"fact_type":"governance_change"},{"claim_id":"5bd891c641d6632880379e4f00e00e0135c30a73","claim":"Allarity Therapeutics, Inc. entered into Modification and Exchange Agreement with 3i, LP (effective 2023-04-20).","evidence_excerpt":"On April 20, 2023, the Company entered into a certain Modification and Exchange Agreement (the “Exchange Agreement”) with 3i","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"3i, LP"},{"label":"Effective","value":"2023-04-20"}],"fact_type":"material_agreement"},{"claim_id":"819d76f24b0b28b3974a75be951ef53a0e892b4e","claim":"Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre (effective 2023-04-19).","evidence_excerpt":"Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre"},{"label":"Effective","value":"2023-04-19"}],"fact_type":"material_agreement"},{"claim_id":"8f43e7fa85556254c0e20ee847c2e72f3eec6e2c","claim":"Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at aggregate gross proceeds of approximately $7.5 million (effective 2023-04-19).","evidence_excerpt":"The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"aggregate gross proceeds of approximately $7.5 million"},{"label":"Effective","value":"2023-04-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}